Combination Chemotherapy in Advanced Adrenocortical Carcinoma
New England Journal of Medicine2012Vol. 366(23), pp. 2189–2197
Citations Over TimeTop 1% of 2012 papers
Martin Faßnacht, Massimo Terzolo, Bruno Allolio, Éric Baudin, Harm R. Haak, Alfredo Berruti, Staffan Welin, Carmen Schade‐Brittinger, André Lacroix, Barbara Jarząb, Halfdan Sørbye, David J. Torpy, Vinzenz Stepan, D.E. Schteingart, Wiebke Arlt, Matthias Kroiß, Sophie Leboulleux, Paola Sperone, Anders Sundin, I G C Hermsen, Stefanie Hahner, Holger S. Willenberg, Antoine Tabarin, Marcus Quinkler, Christelle de la Fouchardière, Martin Schlumberger, Franco Mantero, Dirk Weismann, Felix Beuschlein, Hans Gelderblom, Hanneke Wilmink, Monica Sender, Maureen Edgerly, W. Kenn, Tito Fojo, Hans‐Helge Müller, Britt Skogseid
Abstract
Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, NCT00094497.).
Related Papers
- → Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma(1998)82 cited
- → Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma(1998)48 cited
- → MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer(2019)23 cited
- → Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model(2014)25 cited
- The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation(2017)